PPARA and diabetes mellitus: Combined with the in vivo findings in canine DM and in vitro findings on human epithelial cell cultures, our results point to PPARα agonists as a potential therapeutic target in the prevention and amelioration of intestinal barrier dysfunction and mucosal inflammation.